Allen W. Zhang

Allen W. Zhang

Auto-generated profile, based on publicly available information

Allen W. Zhang

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
AZAllen W. Zhang
Allen W. Zhang
COCiara O’fLanagan
Ciara O’fLanagan
ECElizabeth A. Chavez
Elizabeth A. Chavez
JLJamie L. P. Lim
Jamie L. P. Lim
NCNicholas Ceglia
Nicholas Ceglia
SSSohrab P. Shah
Sohrab P. Shah

1 March 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
TATomohiro Aoki
Tomohiro Aoki
LCLauren C. Chong
Lauren C. Chong
KTKatsuyoshi Takata
Katsuyoshi Takata
KMKaty Milne
Katy Milne
MHMonirath Hav
Monirath Hav
CSChristian Steidl
Christian Steidl
Hodgkin lymphoma is characterized by an extensively dominant tumor microenvironment (TME) composed of different types of noncancerous immune cells with rare malignant cells. Characterization of the cellular components and their spatial relationship is crucial to understanding cross-talk and therapeutic targeting in the TME. We performed single-cell RNA sequencing of more than 127,000 cells from 22 Hodgkin lymphoma tissue specimens and 5 reactive lymph nodes, profiling for the first time the phenotype of the Hodgkin lymphoma–specific immune microenvironment at single-cell resolution. Single-cell expression profiling identified a novel Hodgkin lymphoma–associated subset of T cells with prominent expression of the inhibitory receptor LAG3, and functional analyses established this LAG3+ T-cell population as a mediator of immunosuppression. Multiplexed spatial assessment of immune cells in the microenvironment also revealed increased LAG3+ T cells in the direct vicinity of MHC class II–deficient tumor cells. Our findings provide novel insights into TME biology and suggest new approaches to immune-checkpoint targeting in Hodgkin lymphoma. Significance: We provide detailed functional and spatial characteristics of immune cells in classic Hodgkin lymphoma at single-cell resolution. Specifically, we identified a regulatory T-cell–like immunosuppressive subset of LAG3+ T cells contributing to the immune-escape phenotype. Our insights aid in the development of novel biomarkers and combination treatment strategies targeting immune checkpoints. See related commentary by Fisher and Oh, p. 342. This article is highlighted in the In This Issue feature, p. 327

23 June 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SSSohrab Salehi
Sohrab Salehi
FKFarhia Kabeer
Farhia Kabeer
NCNicholas Ceglia
Nicholas Ceglia
MAMirela Andronescu
Mirela Andronescu
MWMarc J. Williams
Marc J. Williams
SSSohrab P. Shah
Sohrab P. Shah

24 February 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DEDaisuke Ennishi
Daisuke Ennishi
SHShannon Healy
Shannon Healy
ABAli Bashashati
Ali Bashashati
SSSaeed Saberi
Saeed Saberi
CHChristoffer Hother
Christoffer Hother
CSChristian Steidl
Christian Steidl
Transmembrane protein 30A (TMEM30A) maintains the asymmetric distribution of phosphatidylserine, an integral component of the cell membrane and ‘eat-me’ signal recognized by macrophages. Integrative genomic and transcriptomic analysis of diffuse large B-cell lymphoma (DLBCL) from the British Columbia population-based registry uncovered recurrent biallelic TMEM30A loss-of-function mutations, which were associated with a favorable outcome and uniquely observed in DLBCL. Using TMEM30A-knockout systems, increased accumulation of chemotherapy drugs was observed in TMEM30A-knockout cell lines and TMEM30A-mutated primary cells, explaining the improved treatment outcome. Furthermore, we found increased tumor-associated macrophages and an enhanced effect of anti-CD47 blockade limiting tumor growth in TMEM30A-knockout models. By contrast, we show that TMEM30A loss-of-function increases B-cell signaling following antigen stimulation—a mechanism conferring selective advantage during B-cell lymphoma development. Our data highlight a multifaceted role for TMEM30A in B-cell lymphomagenesis, and characterize intrinsic and extrinsic vulnerabilities of cancer cells that can be therapeutically exploited.

22 February 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
TFTyler Funnell
Tyler Funnell
AZAllen W Zhang
Allen W Zhang
DGDiljot Grewal
Diljot Grewal
SMSteven McKinney
Steven McKinney
ABAli Bashashati
Ali Bashashati
SSSohrab P Shah
Sohrab P Shah
Mutation signatures in cancer genomes reflect endogenous and exogenous mutational processes, offering insights into tumour etiology, features for prognostic and biologic stratification and vulnerabilities to be exploited therapeutically. We present a novel machine learning formalism for improved signature inference, based on multi-modal correlated topic models (MMCTM) which can at once infer signatures from both single nucleotide and structural variation counts derived from cancer genome sequencing data. We exemplify the utility of our approach on two hormone driven, DNA repair deficient cancers: breast and ovary (n = 755 samples total). We show how introducing correlated structure both within and between modes of mutation can increase accuracy of signature discovery, particularly in the context of sparse data. Our study emphasizes the importance of integrating multiple mutation modes for signature discovery and patient stratification, and provides a statistical modeling framework to incorporate additional features of interest for future studies. Over time DNA accumulates mutations from a variety of sources. Some mutations result from external mutagens, such as UV radiation, while others result from processes occurring within the cell itself. Each of these sources can impart characteristic patterns of mutations on the genome, known as mutation signatures, which can be detected using computational techniques. Loss of DNA repair mechanisms can leave specific mutation signatures in the genomes of cancer cells. To identify cancers with broken DNA-repair processes, accurate methods are needed for detecting mutation signatures and, in particular, their activities or probabilities within individual cancers. In this paper, we introduce a class of statistical modeling methods used for natural language processing, known as “topic models”, that outperform standard methods for signature analysis. We show that topic models that incorporate signature probability correlations across cancers perform best, while jointly analyzing multiple mutation types improves robustness to low mutation counts.

23 April 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
AMAnthony Mathelier
Anthony Mathelier
CLCalvin Lefebvre
Calvin Lefebvre
AZAllen W Zhang
Allen W Zhang
DADavid J Arenillas
David J Arenillas
JDJiarui Ding
Jiarui Ding
SSSohrab P Shah
Sohrab P Shah
Background: With the rapid increase of whole-genome sequencing of human cancers, an important opportunity to analyze and characterize somatic mutations lying within cis-regulatory regions has emerged. A focus on protein-coding regions to identify nonsense or missense mutations disruptive to protein structure and/or function has led to important insights; however, the impact on gene expression of mutations lying within cis-regulatory regions remains under-explored. We analyzed somatic mutations from 84 matched tumor-normal whole genomes from B-cell lymphomas with accompanying gene expression measurements to elucidate the extent to which these cancers are disrupted by cis-regulatory mutations. Results: We characterize mutations overlapping a high quality set of well-annotated transcription factor binding sites (TFBSs), covering a similar portion of the genome as protein-coding exons. Our results indicate that cis-regulatory mutations overlapping predicted TFBSs are enriched in promoter regions of genes involved in apoptosis or growth/proliferation. By integrating gene expression data with mutation data, our computational approach culminates with identification of cis-regulatory mutations most likely to participate in dysregulation of the gene expression program. The impact can be measured along with protein-coding mutations to highlight key mutations disrupting gene expression and pathways in cancer. Conclusions: Our study yields specific genes with disrupted expression triggered by genomic mutations in either the coding or the regulatory space. It implies that mutated regulatory components of the genome contribute substantially to cancer pathways. Our analyses demonstrate that identifying genomically altered cis-regulatory elements coupled with analysis of gene expression data will augment biological interpretation of mutational landscapes of cancers.